GeoVax Labs Inc.

AI Score

XX

Unlock

1.00
0.15 (17.92%)
At close: Apr 24, 2025, 3:59 PM
1.05
5.11%
Pre-market: Apr 25, 2025, 08:26 AM EDT
17.92%
Bid 1
Market Cap 13.82M
Revenue (ttm) 3.95M
Net Income (ttm) -24.99M
EPS (ttm) -4.82
PE Ratio (ttm) -0.21
Forward PE -0.84
Analyst Buy
Ask 1.05
Volume 929,828
Avg. Volume (20D) 596,432
Open 0.86
Previous Close 0.85
Day's Range 0.86 - 1.12
52-Week Range 0.73 - 11.18
Beta 3.71

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, ch...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 17
Stock Exchange NASDAQ
Ticker Symbol GOVX
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 1351.60% from the latest price.

Stock Forecasts
1 week ago
-20.5%
GeoVax Labs shares are trading lower after multipl... Unlock content with Pro Subscription
1 week ago
+4.9%
GeoVax Labs shares are trading lower after the company announced it received a notification from Advanced Technology International to stop all work on its efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; "NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine"